Podcast
Lung Cancer Update
Hosted by Dr. Neil Love · EN
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.
30episodes
Episodes
Newest firstAll episodes
EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
2w ago01:57:57Tap to summarizeFeaturing perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (00:00)Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Prof Passaro (2:27)EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC — Dr Neal (36:08)Utility of TROP2-Targeted Antibody-Drug Conjugates in the Management of EGFR-Mutant NSCLC — Dr Sands (56:16)Emerging Role of Bispecific Antibody-Based Approaches for EGFR-Mutated NSCLC — Dr Goldman (1:19:08)Tolerability Considerations with the Use of Available and Emerging Therapies for EGFR-Mutated NSCLC — Dr Goldberg (1:38:46)CME information and select publications
Transcribe →HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review
3w ago00:27:32Tap to summarizeFeaturing an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics:Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line zongertinib (0:00)Case: A woman in her early 60s with multiregimen-recurrent HER2-mutant metastatic NSCLC experiences a response to zongertinib (8:07)Case: A man in his mid 80s experiences metastatic recurrence after resection of PD-L1-positive, HER2-mutant metastatic NSCLC (17:50)CME information and select publications
Transcribe →Nonmetastatic Non-Small Cell Lung Cancer — An Interview with Dr Jamie E Chaft
4w ago00:59:55Tap to summarizeFeaturing an interview with Dr Jamie E Chaft, including the following topics: Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treated with induction therapy and surgery (00:00)Available clinical data with immunotherapy in the neoadjuvant, perioperative and adjuvant settings (07:45)Factors in the selection of adjuvant immunotherapy, including circulating tumor DNA (11:39)Evolving approaches to management, including systemic therapy, surgery and radiation therapy techniques (19:28)Case: A woman in her early 60s with nonmetastatic non-small cell lung cancer (NSCLC) and an EGFR exon 19 deletion who is enrolled in the NeoADAURA study (24:03)Importance of clinical trials in the adjuvant setting (33:02)Data surrounding treatment in the neoadjuvant setting; key implications of the NeoADAURA study (35:41)Case: A man in his late 60s with a history of smoking and Stage III T4N3 NSCLC not otherwise specified with low PD-L1 expression, high tumor mutation burden, microsatellite stability and an STK11 mutation (41:34)Selecting patients for the NeoADAURA study treatment approach; deciding between chemoimmunotherapy and chemoradiation therapy (51:01)CME information and select publications
Transcribe →For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress
4w ago01:28:54Tap to summarizeFeaturing perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:Introduction (0:00)Overview of Antibody-Drug Conjugates (ADCs) (2:07)Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)Currently Available ADCs for Gynecologic Cancer Management (26:37)Currently Available ADCs for Lung Cancer Management (44:07)Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)NCPD information and select publications
Transcribe →Targeted Therapies for Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit
Jun 3000:50:08Tap to summarizeFeaturing perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00)Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09)Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56)CME information and select publications
Transcribe →EGFR-Mutated Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit
Jun 2700:51:09Tap to summarizeFeaturing perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics:Introduction (0:00)Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (0:38)Nonmetastatic EGFR-Mutated NSCLC, Exon 20 Insertion Mutations and Novel Agents — Dr Piotrowska (33:20)CME information and select publications
Transcribe →First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck
Jun 1800:40:45Tap to summarizeFeaturing an interview with Prof Martin Reck, including the following topics:Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)Considerations with maintenance therapy for ES-SCLC (9:31)Considerations with immunotherapy for ES-SCLC (13:12)Curability of SCLC with systemic therapy (15:17)Data with chemoimmunotherapy for patients with poor performance status (25:55)Future developments in therapy for SCLC (30:11)Rapid fire: Small Cell 101 (35:45)CME information and select publications
Transcribe →Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Jun 900:58:47Tap to summarizeDr Christine L Hann from the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding the management of SCLC.CME information and select publications
Transcribe →EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Apr 2700:57:26Tap to summarizeDr Suresh S Ramalingam and Dr Helena Yu discuss the selection and sequencing of therapy for patients with EGFR mutation-positive non-small cell lung cancer and summarize major advances in the treatment landscape reported over the past year. CME information and select publications here.
Transcribe →Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Apr 1700:27:12Tap to summarizeDr Natalie Vokes from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of lung cancer. CME information and select publications here.
Transcribe →